Epidemiology and Antifungal Susceptibility Profile of Aspergillus Species: Comparison between Environmental and Clinical Isolates from Patients with Hematologic Malignancies-Reference-Cited by-同舟云学术

Epidemiology and Antifungal Susceptibility Profile of Aspergillus Species: Comparison between Environmental and Clinical Isolates from Patients with Hematologic Malignancies

Published:2019-07 Issue:7 Volume:57 Page:
ISSN:0095-1137
Container-title:Journal of Clinical Microbiology
language:en
Short-container-title:J Clin Microbiol

Author:

Cho Sung-Yeon¹²³,Lee Dong-Gun¹²³^ORCID,Kim Won-Bok²,Chun Hye-Sun²,Park Chulmin²,Myong Jun-Pyo⁴,Park Yeon-Joon⁵,Choi Jae-Ki¹²,Lee Hyo-Jin¹²,Kim Si-Hyun¹²,Park Sun Hee¹²,Choi Su-Mi¹²,Choi Jung-Hyun¹²,Yoo Jin-Hong¹²

Affiliation:

1. Division of Infectious Diseases, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea

2. Vaccine Bio Research Institute, The Catholic University of Korea, Seoul, Republic of Korea

3. Catholic Hematology Hospital, Seoul, Republic of Korea

4. Occupational and Environmental Medicine, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea

5. Department of Laboratory Medicine, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea

Abstract

Global data on the epidemiology and susceptibility of Aspergillus are crucial in the management of invasive aspergillosis. Here, we aimed to determine the characteristics of clinical and environmental Aspergillus isolates, focusing mainly on hematologic malignancy patients.

Funder

Ministry of Health and Welfare

Publisher

American Society for Microbiology

Subject

Microbiology (medical)

Link

https://journals.asm.org/doi/pdf/10.1128/JCM.02023-18

Reference44 articles.

1. Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline

2. Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America

3. Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial